Table of Contents
The Vaccines Market Outlook To 2014
Executive summary 10
Vaccines and vaccine-preventable diseases 10
Overview of the global vaccines market 11
Pediatric vaccines 12
Adult vaccines 13
Pipeline analysis 14
Competitive landscape 15

Chapter 1 Scope and methodology 18
Scope 18
Methodology 19

Chapter 2 Vaccines and vaccine-preventable diseases 22
Summary 22
Introduction 23
Vaccines and the immune system 23
The immune system 23
Immunity by vaccination 24
The history of vaccination 24
Types of vaccines 26
Hurdles in vaccine development 27
Vaccine-preventable diseases 29
Measles 29
Mumps 30
Rubella 30
Diphtheria 31
Tetanus 31
iv
Pertussis 32
Meningitis (pneumococcus, meningococcus and Hib) 32
Varicella 33
Hepatitis 33
Influenza 34
Typhoid 35
Rabies 35

Chapter 3 Overview of the global vaccines market 38
Summary 38
Introduction 39
Key trends, issues and events 39
Prophylactic cancer vaccines redefine the market 39
US health reforms and VFC recommendations may influence vaccines sales 40
Therapeutic vaccines: a franchise in the making 40
Cell culture and adjuvant technology: next-generation vaccine engineering 41
Seasonal influenza vaccines: key to continuous revenue generation 42
Novel combination vaccines driving growth of vaccines for infectious
diseases 42
Leading vaccine brands 44
Sales forecasts of leading vaccine brands 45
Country market analysis 47
Leading players in the vaccines market 48

Chapter 4 Pediatric vaccines 50
Summary 50
Introduction 51
Pediatric immunization schedule 51
Pediatric vaccine population 53
Pneumococcal vaccines 54
Leading brands 55
Competitive analysis 55
Diphtheria, tetanus and pertussis (DTP) vaccines 56
Leading brands 57
Competitive analysis 57
Measles, mumps and rubella (MMR) vaccines 58
Leading brands 59
Competitive analysis 60
Market transition from MMR to MMRV 60
v
Rotaviral vaccines 62
Leading rotaviral vaccine brands 63
Competitive analysis 63
Meningococcal vaccines 64
Leading meningococcal vaccine brands 65
Competitive analysis 65
Other pediatric vaccines 67
Leading brands 67
Competitive analysis 68

Chapter 5 Adult vaccines 72
Summary 72
Introduction 73
Adult vaccine population 74
Adolescent vaccination 74
Elderly vaccination 75
Traveler vaccination 75
Hepatitis vaccines 76
Leading brands 77
Competitive analysis 78
Influenza vaccines 79
H1N1 swine flu 80
Leading brands 81
Competitive analysis 81
Human papillomavirus (HPV) vaccines 82
Leading brands 83
Competitive analysis 83
Other adult vaccines 86
Leading brands 87

Chapter 6 Pipeline analysis 90
Summary 90
Introduction 91
Vaccines under research and development 91
Prevnar 13vPnC 93
Menveo 94
MenB 95
Cervarix 97
Synflorix 98
Ixiaro/Jespect 100
Newer vaccine strategies: DNA and therapeutic vaccines 101
DNA vaccines 101
Therapeutic vaccines 102
Provenge 106
Pipeline forecasts 107

Chapter 7 Competitive landscape 110
Summary 110
Introduction 111
Market concentration/fragmentation analysis 111
Segment wise positioning of the five major players 112
Forecast sales of leading players in the global vaccines market, 2008–14 113
Merck 113
Overview 113
Marketed portfolio 114
Pipeline portfolio 114
Licensing agreements/mergers/acquisitions 116
Strategic and growth analysis 116
GSK 119
Overview 119
Marketed portfolio 120
Pipeline portfolio 121
Licensing agreements/mergers/acquisitions 122
Strategic and growth analysis 123
Wyeth 126
Overview 126
Marketed portfolio 127
Pipeline portfolio 127
Licensing agreements/mergers/acquisitions 128
Strategic and growth analysis 129
Sanofi-Aventis 131
Overview 131
Marketed portfolio 131
Pipeline portfolio 132
Licensing agreements/mergers/acquisitions 135
Strategic and growth analysis 135
Novartis 139
Overview 139
Marketed portfolio 139
Pipeline portfolio 140
Licensing agreements/mergers/acquisitions 143
Strategic and growth analysis 143

Chapter 8 Appendix 148
Herfindahl Index 148
Glossary 149

List of Figures
Figure 2.1: Brief history of vaccines and the future 25
Figure 4.2: Pediatric vaccination schedule for the US and 5EU, 2008 52
Figure 6.3: Key recent and expected launches, 2009–14 92
Figure 6.4: Ongoing clinical trials of therapeutic vaccines for cancer and HIV/AIDS, May 2009
104
Figure 7.5: Competitive position of leading companies across market segments, 2008 112

List of Tables
Table 2.1: Vaccine-preventable diseases 29
Table 3.2: Global sales of leading vaccine brands, 2008 44
Table 3.3: Sales forecast of leading vaccine brands, 2008–14 45
Table 3.4: 7MM, 7EM and global sales of vaccine types (ATC classes), 2008 46
Table 3.5: Sales of vaccines by country 47
Table 3.6: Global sales of leading vaccine players, 2008 48
Table 4.7: Births and catch-up population across the 7MM and 7EM, 2008 53
Table 4.8: Leading pneumococcal vaccine brands, 2008 55
Table 4.9: Leading DTP vaccine brands, 2008 57
Table 4.10: Leading MMR vaccine brands, 2008 59
Table 4.11: Leading rotaviral vaccine brands, 2008 63
Table 4.12: Leading meningococcal vaccine brands, 2008 65
Table 4.13: Prevalence pattern of Neisseria meningitidis serotypes 65
Table 4.14: Other leading pediatric vaccines, 2008 67
Table 5.15: Adolescent, adult and elderly population across the 7MM and 7EM, 2008 74
Table 5.16: Traveler vaccines 76
Table 5.17: Leading hepatitis vaccine brands, 2008 77
Table 5.18: Leading influenza vaccine brands, 2008 81
Table 5.19: Leading HPV vaccine brands, 2008 83
Table 5.20: Other leading adult vaccine brands, 2008 87
Table 6.21: An overview of Prevnar 13vPnC 93
Table 6.22: An overview of Menveo 94
Table 6.23: An overview of MenB 95
Table 6.24: An overview of Cervarix 97
Table 6.25: An overview of Synflorix 98
Table 6.26: An overview of Ixiaro 100
Table 6.27: Status quo of conceptualized therapeutic vaccines 105
Table 6.28: An overview of Provenge 106
Table 6.29: Sales forecast of leading recently marketed or late-stage pipeline vaccine candidates,
2008–14 107
Table 7.30: Sales forecast of the leading players in the global vaccines market, 2008–14 113
Table 7.31: Merck’s leading vaccine brands, 2008 114
Table 7.32: Merck’s key vaccines under development, June 2009 115
Table 7.33: Deals and alliances involving Merck, May 2009 116
Table 7.34: GSK’s leading vaccine brands, 2008 120
Table 7.35: GSK’s key vaccines under development, May 2009 121
Table 7.36: Deals and alliances involving GSK, May 2009 122
Table 7.37: Wyeth’s leading vaccine brands, 2008 127
Table 7.38: Wyeth’s key vaccines under development, May 2009 128
Table 7.39: Deals and alliances involving Wyeth, May 2009 128
Table 7.40: Sanofi-Aventis’ leading vaccine brands, 2008 131
Table 7.41: Sanofi-Aventis’ key vaccines under development, May 2009 133
Table 7.42: Deals and alliances involving Sanofi-Aventis, May 2009 135
Table 7.43: Novartis’ leading vaccine brands, 2008 139
Table 7.44: Novartis’ key vaccines under development, May 2009 140
Table 7.45: Deals and alliances involving Novartis, May 2009 143